84 related articles for article (PubMed ID: 4741528)
1. Morphological changes in the liver of rats treated with a new hypolipidemic agent, S-8527.
Sakamoto SI; Yamada K; Anzai T; Wada T
Atherosclerosis; 1973; 18(1):109-16. PubMed ID: 4741528
[No Abstract] [Full Text] [Related]
2. Hypolipidemic action of a new aryloxy compound (S-8527) in rats.
Toki K; Nakamura Y; Agatsuma K; Nakatani H; Aono S
Atherosclerosis; 1973; 18(1):101-8. PubMed ID: 4741527
[No Abstract] [Full Text] [Related]
3. The influence of 1,1-bis(4'-(1"-carboxy-1"-methylpropoxy)-phenyl)cyclohexane (a new aryloxy compound, S-8527) on cholesterol metabolism in rats.
Kritchevsky D; Tepper SA
Atherosclerosis; 1973; 18(1):93-9. PubMed ID: 4741537
[No Abstract] [Full Text] [Related]
4. Effects of S-8527 (1,1-bis(4'-(1'-carboxy-1'-methylpropoxy)phenyl) cyclohexane), a new hypolipidemic compound, on cholesterol and lipoprotein metabolism in rats.
Suzuki K
Biochem Pharmacol; 1976 Feb; 25(3):325-8. PubMed ID: 1267828
[No Abstract] [Full Text] [Related]
5. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.
Barnard SD; Molello JA; Caldwell WJ; LeBeau JE
J Toxicol Environ Health; 1980 May; 6(3):547-57. PubMed ID: 7420463
[TBL] [Abstract][Full Text] [Related]
6. Polydispersity of rat liver peroxisomes induced by the hypolipidemic and carcinogenic agent clofibrate.
Flatmark T; Christiansen EN; Kryvi H
Eur J Cell Biol; 1981 Apr; 24(1):62-9. PubMed ID: 7238535
[TBL] [Abstract][Full Text] [Related]
7. Action of tiadenol and clofibrate on biliary excretions of cholesterol and bile salts in rats.
Fredj G; Clenet M; Cuchet P; Rousselet F; Rozé C
Digestion; 1979; 19(4):228-36. PubMed ID: 478204
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of the hypolipidaemic agents ICI53072 and clofibrate with those of phenobarbitone on liver size, blood flow and DNA content in the rat.
Berman JS; Hiley CR; Wilson AC
Br J Pharmacol; 1983 Mar; 78(3):533-41. PubMed ID: 6839062
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clofibrate and ethyl-5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate induced changes in serum lipoprotein cholesterol and hepatic peroxisome proliferation in the normal rat.
Stevens TJ; Stafford WW; Day CE; Block EM
Artery; 1983; 12(2):81-94. PubMed ID: 6678582
[TBL] [Abstract][Full Text] [Related]
10. Aminophenyl ether compound (YM-95831), a new hypolipidemic agent with a high density lipoprotein elevating activity in rats.
Ohata I; Sakamoto N; Nitatori R; Maeno H
Arzneimittelforschung; 1983; 33(2):237-41. PubMed ID: 6682662
[TBL] [Abstract][Full Text] [Related]
11. A kinetic comparison of the physiological effects of clofibrate and clofenapate in the rat.
Krishnakantha TP; Kurup CK
Environ Physiol Biochem; 1974; 4(2):80-8. PubMed ID: 4459126
[No Abstract] [Full Text] [Related]
12. Lentysine: a new hypolipidemic agent from a mushroom.
Rokujo T; Kikuchi H; Tensho A; Tsukitani Y; Takenawa T; Yoshida K; Kamiya T
Life Sci; 1970 Apr; 9(7):379-85. PubMed ID: 5463059
[No Abstract] [Full Text] [Related]
13. [Characterization of clofibrate-stimulated alkaline phosphatase in rat liver].
Popova SV; Antonenkov VD; Panchenko LF
Vopr Med Khim; 1983; 29(4):78-83. PubMed ID: 6623998
[TBL] [Abstract][Full Text] [Related]
14. Structure of hepatic microbodies in rats treated with acetylsalicylic acid, clofibrate, and dimethrin.
Hruban Z; Gotoh M; Slesers A; Chou SF
Lab Invest; 1974 Jan; 30(1):64-75. PubMed ID: 4812810
[No Abstract] [Full Text] [Related]
15. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats.
Suzuki K
Biochem Pharmacol; 1975 Jun; 24(11-12):1203-7. PubMed ID: 237511
[No Abstract] [Full Text] [Related]
16. Relationship of serum triglyceride lowering to changes in hepatic composition induced by different classes of drugs.
Dalton C; Hope WC; Hope HR; Sheppard H
Biochem Pharmacol; 1974 Feb; 23(3):685-96. PubMed ID: 4150813
[No Abstract] [Full Text] [Related]
17. Effect of clofibrate on plasma lipid concentration and liver malic enzyme gene expression in rats with experimental chronic renal failure.
Korczyńska J; Stelmańska E; Nieweglowski T; Szołkiewicz M; Rutkowski B; Swierczyński J
Pol J Pharmacol; 2000; 52(4):291-7. PubMed ID: 11345485
[TBL] [Abstract][Full Text] [Related]
18. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
Reddy J; Svoboda D; Azarnoff D
Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
[No Abstract] [Full Text] [Related]
19. Studies on hypolipidemic agents. III. Comparison of the hypolipidemic properties of 5-tridecylpyrazole-3-carboxylic acid and clofibrate.
Seki K; Fukuda M; Isegawa J; Ohki M
Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4103-9. PubMed ID: 6529804
[No Abstract] [Full Text] [Related]
20. [Comparative biochemical and ultrastructural study of the hepatic response induced in the rat by 2 hypolipemic agents: clofibrate and itanoxone].
Gendre PM; Marcelon G; Delhon A; Lauressergues H; Fauran F
J Pharmacol; 1984; 15(2):209-22. PubMed ID: 6738078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
